Finding the right CE Marking consultant for EU MDR or IVDR compliance can make or break your market entry into Europe. With over 3,000 US medical device and IVD manufacturers actively pursuing CE Marking under the new EU MDR 2017/745 and IVDR 2017/746 regulations, choosing an experienced regulatory partner has never been more critical. This guide ranks the Top 10 CE Marking Consultants for MDR and IVDR in the USA in 2026 — evaluated on regulatory depth, Notified Body relationships, technical documentation expertise, and proven client outcomes.

“Whether you manufacture a low risk Class I device or higher class IIa, IIb or Class III implantable device or a low risk class A/B, or higher risk class C/D IVD, this guide helps you identify the right CE Marking consultant matched to your device type, regulatory pathway, and budget.”

The need and urgency of finding right consulting firms increased dramatically after the release of New EU MDR 2017/745 and EU IVDR 2017/746.

CE Marking is a mandatory regulatory certification that allows medical devices and in vitro diagnostic (IVD) products to be legally sold across all 27 European Union member states, as well as in EEA countries including Norway, Iceland, and Liechtenstein. The “CE” stands for Conformité Européenne — French for European Conformity — and the CE Mark on a device signals to regulators, healthcare providers, and patients that the product meets all applicable EU safety, performance, and quality requirements.

For US medical device and IVD manufacturers, CE Marking is not optional — it is the only legal pathway to market entry in Europe. Without it, no US manufacturer can sell, distribute, or clinically deploy their device anywhere in the EU, regardless of whether the product already holds FDA 510(k) clearance or PMA approval. FDA clearance carries no automatic recognition or equivalence in Europe. The two regulatory systems are entirely independent, and US manufacturers must meet EU requirements in full.

The EU Medical Device Regulation (MDR) 2017/745 replaced the legacy Medical Device Directive (MDD 93/42/EEC) and has been fully enforced since May 2021 for new devices, with extended transition deadlines for legacy MDD-certified devices running through 2028. Under MDR, CE Marking requirements are significantly more demanding than under the old MDD framework.

The EU In Vitro Diagnostic Regulation (IVDR) 2017/746 replaced the In Vitro Diagnostic Directive (IVDD 98/79/EC) and introduced a sweeping overhaul of how IVD devices are regulated in Europe. IVDR is widely regarded as one of the most demanding regulatory transitions in the history of the IVD industry, with the vast majority of previously self-certified IVDs now requiring Notified Body involvement for the first time.

The European medical device market is the second largest in the world, valued at over €120 billion, and represents a critical revenue opportunity for US manufacturers seeking international market expansion. Beyond revenue, CE Marking unlocks access to:

• All 27 EU member states with a single certification — no country-by-country approvals
• EEA markets — Norway, Iceland, Liechtenstein
• Mutual recognition markets — several non-EU countries accept CE Marking as a baseline for their own approval processes, including Switzerland, Turkey, and the UK (UKCA transitional arrangements)
• Investor and acquirer confidence — CE Marking is often a prerequisite for Series B/C funding rounds and M&A due diligence in the medical device sector
• Clinical study access — CE Marking enables participation in EU-based clinical investigations and registry studies

For US manufacturers already holding FDA clearance, CE Marking is the natural next step in a global market access strategy. However, the technical, clinical, and regulatory gap between FDA and EU MDR/IVDR requirements is substantial — and attempting CE Marking without experienced consultants significantly increases the risk of Notified Body rejection, costly rework, and delayed market entry.

• Technical Documentation Preparation
• Clinical Evaluation and Performance Evaluation Reports
• Notified Body Selection and Liaison
• Post-Market Surveillance (PMS) and Vigilance Support
• EUDAMED Registration and UDI Implementation

MEDDEVICECORP

Advantages using MedDeviceCorp Services
Disadvantages using MedDeviceCorp Services

EMERGO

Advantages using Emergo Services
Disadvantages using Emergo Services

I3CGLOBAL

Advantages using I3CGlobal Services
Disadvantages using I3CGlobal Services

RQM+ 

Advantages using RQM+ Services
Disadvantages using RQM+ Services

RQM+ 

Advantages using RQM+ Services
Disadvantages using RQM+ Services

FREYR

Advantages using Freyr Services
Disadvantages using Freyr Services

REGHELPS

Advantages using Reghelps Services
Disadvantages using Reghelps Services

CASCUS

Advantages using Cascus Services
Disadvantages using Cascus Services

RCA PROMPT

Advantages using Reghelps Services
Disadvantages using Reghelps Services

PROPHARMA

Advantages using Reghelps Services
Disadvantages using Reghelps Services